Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.44 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12596392 | 0.85 | GPR119 (0.56) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL12596724 | 0.84 | YTHDC1 (0.40) | GPR119YTHDC1CYP3A4CYP2C9ADORA3 | |
| SCHEMBL12596381 | 0.84 | GPR119 (0.66) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL10169942 | 0.81 | GPR119 (0.54) | GPR119YTHDC1CYP3A4CYP2C9ADORA3 | |
| SCHEMBL304338 | 0.79 | GPR119 (0.60) | GPR119YTHDC1CYP3A4CYP2C9 | |
| SCHEMBL866007 | 0.78 | GPR119 (0.59) | GPR119YTHDC1CYP3A4CYP2C9 | |
| SCHEMBL304233 | 0.78 | GPR119 (0.53) | GPR119YTHDC1CYP3A4CYP2C9 | |
| SCHEMBL12596419 | 0.77 | GPR119 (0.71) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL10137743 | 0.77 | GPR119 (0.66) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL10151293 | 0.75 | GPR119 (0.77) | GPR119CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | SCHERING CORPORATION | 2011-05-19 | — | — | US | disclosed |
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | SCHERING CORPORATION | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | GPR119, GCGR, GPR35 | GPR119 1/4885YTHDC1 2705/4885CYP3A4 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.